These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22072555)

  • 1. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
    Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
    Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model.
    Krause DS; Van Etten RA
    Blood; 2004 Dec; 104(13):4236-44. PubMed ID: 15308567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
    Sefrioui H; Billiau AD; Waer M
    Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Baurmann H; Nagel S; Binder T; Neubauer A; Siegert W; Huhn D
    Blood; 1998 Nov; 92(10):3582-90. PubMed ID: 9808551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
    Matte CC; Cormier J; Anderson BE; Athanasiadis I; Liu J; Emerson SG; Pear W; Shlomchik WD
    Blood; 2004 Jun; 103(11):4353-61. PubMed ID: 14982874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
    Chakraverty R; Eom HS; Sachs J; Buchli J; Cotter P; Hsu R; Zhao G; Sykes M
    Blood; 2006 Sep; 108(6):2106-13. PubMed ID: 16757687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro.
    Kondo Y; Shiobara S; Nakao S
    Exp Hematol; 2001 Apr; 29(4):471-6. PubMed ID: 11301187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
    Slavin S; Nagler A; Varadi G; Or R
    Exp Hematol; 2000 Jul; 28(7):853-7. PubMed ID: 10907647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
    Young FM; Campbell A; Emo KL; Jansson J; Wang PY; Jordan CT; Mullen CA
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):622-30. PubMed ID: 18489987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.
    Shimoni A; Gajewski JA; Donato M; Martin T; O'Brien S; Talpaz M; Cohen A; Korbling M; Champlin R; Giralt S
    Biol Blood Marrow Transplant; 2001; 7(10):568-75. PubMed ID: 11760089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
    Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease.
    Zheng H; Matte-Martone C; Li H; Anderson BE; Venketesan S; Sheng Tan H; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Feb; 111(4):2476-84. PubMed ID: 18045967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel minor histocompatibility antigens responsible for graft-versus-leukemia (GVL) effect on chronic myeloid leukemia: usefulness of determining the clonotype of T cells associated with GVL effect after donor leukocyte infusion.
    Nakao S
    Int J Hematol; 2002 Aug; 76 Suppl 1():274-6. PubMed ID: 12430863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.